Fig. 5From: Clinical and economic impact of ‘ROS1-testing’ strategy compared to a ‘no-ROS1-testing’ strategy in advanced NSCLC in SpainPSA results of 1000 simulations provided by incremental cost-effectiveness plane. QALY: quality-adjusted life yearsBack to article page